methotrexate has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (90.48) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Atwell, S; Brooks, HB; Dally, RD; Durham, TB; Fales, KR; Frimpong, K; Geeganage, S; Hui, YH; Konicek, SA; Lee, MR; Margolis, BJ; Mc Cowan, JR; Meier, TI; Njoroge, FG; Roth, KD; Shepherd, TA; Si, C; Thibodeaux, S; Thrasher, KJ; Torrado, A; Toth, JL; Wang, J; Wang, Y; Wu, Z | 1 |
| Abedi, M; Javanmardi, S; Mohammad Tamaddon, A; Mohebi, Y; Najafi, H; Sadat Abolmaali, S; Zarenejad, S | 1 |
| Cao, Z; Hua, Z; Li, Y; Liu, R; Liu, Y; Lu, A; Lu, C; Luo, X; Wang, X; Xue, Z; Zhang, Z | 1 |
| Gwak, H; Jeon, YW; Kang, EY; Kim, SY; Lee, HJ; Lim, ST; Moon, BI; Nam, SJ; Park, CH; Suh, YJ | 1 |
| Chen, YH; Hung, YT; Wei, CW; Yiang, GT; Yu, YL | 1 |
| Bagnardi, V; Cataliotti, L; Curigliano, G; D'Aiuto, G; Disalvatore, D; Goldhirsch, A; Greco, M; Mastropasqua, MG; Orecchia, R; Talakhadze, N; Viale, G; Zurrida, S | 1 |
| Datti, A; Egan, SE; Liu, JC; Maclean, N; Robinson, TJ; Schimmer, AD; Sun, T; Vizeacoumar, F; Zacksenhaus, E | 1 |
| Amadori, D; Biglia, N; Brandi, M; Bravaccini, S; Cerasoli, S; Faedi, M; Gianni, L; Giunchi, DC; Maltoni, R; Mangia, A; Medri, L; Paradiso, A; Petroni, S; Puccetti, M; Ricci, M; Rocca, A; Scarpi, E; Serra, L; Silvestrini, R; Sismondi, P; Tienghi, A | 1 |
| Bartsch, R; Berghoff, AS; Dubsky, P; Fitzal, F; Foedermayr, M; Gnant, M; Preusser, M; Promberger, R; Rudas, M; Sebesta, M; Steger, GG; Weltermann, A; Zach, O; Zielinski, CC | 1 |
| Itoh, F; Maeda, I; Miyoshi, Y; Ohta, T; Oikawa, R; Tsuchiya, K; Tsugawa, K; Watanabe, Y; Wu, W | 1 |
| Chang, HK; Chen, SC; Hsueh, S; Lin, YC; Lo, YF; Wu, CE | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Fushimi, K; Takami, M; Tanabe, N | 1 |
| Ambrogi, F; Ardoino, I; Biganzoli, E; Boracchi, P; Coradini, D; Daidone, MG; Demicheli, R; Moliterni, A | 1 |
| Firger, J | 1 |
| Broggini, M; Cavalli, IJ; Chilà, R; Damia, G; de Lima, RS; de Oliveira, SF; Ganzinelli, M; Generali, D; Maciel, ME; Ribeiro, EM; Serino, L; Urban, Cde A | 1 |
| Cochereau, D; Cochereau, J; Da Costa, S; Espié, M; Gauthier, H; Giacchetti, S; Le Maignan, C; Teixeira, L | 1 |
| Abdi, EA; Cagossi, K; Chirgwin, J; Coates, AS; Colleoni, M; Eniu, A; Gelber, RD; Gelber, S; Gianni, L; Goldhirsch, A; Gomez, HL; Gray, KP; Kralidis, E; Láng, I; Linderholm, BK; Price, KN; Puglisi, F; Rauch, D; Regan, MM; Thürlimann, B; Tondini, C; Viale, G | 1 |
| Cancello, G; Colleoni, M; Criscitiello, C; Curigliano, G; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Kammler, R; Láng, I; Munzone, E; Price, KN; Pruneri, G; Regan, MM; Ruhstaller, T; Viale, G; Vingiani, A | 1 |
| Lam, HB; Yen, CF | 1 |
| Hung, YT; Liu, HC; Wei, CW; Wu, CW; Yiang, GT; Yu, YL | 1 |
6 trial(s) available for methotrexate and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymph Nodes; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms | 2014 |
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; DNA Methylation; Female; Fluorouracil; Genes, BRCA1; Genes, p53; Germ-Line Mutation; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paraffin Embedding; Prospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2014 |
p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Genes, p53; Humans; Mastectomy; Methotrexate; Neoplasm Recurrence, Local; Phenotype; Prognosis; Prospective Studies; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2015 |
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Humans; Methotrexate; Middle Aged; Triple Negative Breast Neoplasms; Young Adult | 2016 |
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Topics: Administration, Metronomic; Adult; Aged; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Maintenance Chemotherapy; Methotrexate; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
15 other study(ies) available for methotrexate and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhi
Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Female; Folic Acid Antagonists; Humans; Male; Mice; Mice, Nude; Models, Molecular; Phosphoribosylaminoimidazolecarboxamide Formyltransferase; Sulfonamides; Thiophenes; Triple Negative Breast Neoplasms | 2017 |
Biotin receptor-targeting nanogels loaded with methotrexate for enhanced antitumor efficacy in triple-negative breast cancer in vitro and in vivo models.
Topics: Animals; Biotin; Drug Carriers; Drug Delivery Systems; Humans; Methotrexate; Mice; Nanogels; Receptors, Growth Factor; Triple Negative Breast Neoplasms | 2022 |
MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Methotrexate; Micelles; Polymers; Triple Negative Breast Neoplasms | 2023 |
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Registries; Republic of Korea; Retrospective Studies; Survival Analysis; Triple Negative Breast Neoplasms | 2018 |
Anticancer effects of methotrexate in combination with α‑tocopherol and α‑tocopherol succinate on triple‑negative breast cancer.
Topics: alpha-Tocopherol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Methotrexate; Triple Negative Breast Neoplasms | 2019 |
RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Gamma Rays; Humans; Methotrexate; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Retinoblastoma Protein; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Repair; Docetaxel; Female; Fluorouracil; Homologous Recombination; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Taxoids; Triple Negative Breast Neoplasms | 2013 |
Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2014 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
[A retrospective study of tegafur/uracil compared with cyclophosphamide, methotrexate, and fluorouracil as adjuvant chemotherapy in patients with node-negative, triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Recurrence; Retrospective Studies; Tegafur; Triple Negative Breast Neoplasms; Uracil | 2014 |
Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Methotrexate; Nitric Oxide; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Triple Negative Breast Neoplasms | 2015 |
Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Azacitidine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Estrogen Receptor alpha; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Methotrexate; Organ Specificity; Promoter Regions, Genetic; Purine-Nucleoside Phosphorylase; Receptor, ErbB-2; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Triple Negative Breast Neoplasms | 2016 |
[Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arachnoiditis; Breast Neoplasms; Clinical Protocols; Drug Administration Schedule; Female; Humans; Injections, Spinal; Meningeal Carcinomatosis; Methotrexate; Middle Aged; Paris; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Triple Negative Breast Neoplasms | 2016 |
Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluorouracil; Humans; Methotrexate; Neoplasms, Multiple Primary; Triple Negative Breast Neoplasms | 2016 |
Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways.
Topics: Ascorbic Acid; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; MAP Kinase Signaling System; MCF-7 Cells; Methotrexate; Triple Negative Breast Neoplasms | 2017 |